Diagnostic Center | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Currently, Praveen Akkinepally is the Head of Lung Cancer Commercialization, AstraZeneca Gaithersburg, MD, USA
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Subscribe To Our Newsletter & Stay Updated
